Edgar Filing: PTC THERAPEUTICS, INC. - Form 4

PTC THERA Form 4 January 30, 2	PEUTICS, INC										
								OMB A	PPROVAL		
FORM	UNITED	STATES	S SECURITIES AND EXCHANGE COMMISSIC Washington, D.C. 20549					N OMB Number:	3235-0287		
Check this if no long	or			U U				Expires:	January 31,		
subject to Section 10 Form 4 or	5. 5.	AENT OF		SECUI	Estimated burden hou response	urs per					
Form 5 obligations may continue.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19401(b).30(h) of the Investment Company Act of 1940											
(Print or Type R	esponses)										
1. Name and Address of Reporting Person <u>*</u> Boulding Mark Elliott			2. Issuer Name and Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer				
		PTC THERAPEUTICS, INC. [PTCT]				(Check all applicable)					
(Last)	Middle)	3. Date of Earliest Transaction (Month/Day/Year)				Director 10% Owner X Officer (give title Other (specify					
	IERAPEUTICS, ORPORATE CO		01/28/2014				below) below) Exec. VP, and CLO				
SOUTH DI	(Street)	07080	4. If Amendment, Date Original Filed(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
							Person				
(City)	(State)	(Zip)	Tab	ole I - Non-	Derivative	Securities A	cquired, Disposed of	of, or Beneficia	lly Owned		
	2. Transaction Date (Month/Day/Year)		Date, if	Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, 4)	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Repo	ort on a separate line	e for each cla	ass of sec	urities bene	Perso inform requir	ons who res nation cont red to resp ays a curre	or indirectly. spond to the colle ained in this form ond unless the for ntly valid OMB co	i are not rm	SEC 1474 (9-02)		
	Tab					sposed of, or convertible :	Beneficially Owned securities)	I			

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and	Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying	Securities	D

Edgar Filing: PTC THERAPEUTICS, INC. - Form 4

	Security (Instr. 3)	•		any (Month/E	Day/Year)	Code (Instr. 8)	Securities Acquired (or Dispose (D) (Instr. 3, 4 and 5)	d of	(Month/Day/	Year)	(Instr. 3 and 4)		S (
						Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
	Stock Option (right to buy)	\$ 27.05	01/28/2014			A	80,000		<u>(1)</u>	01/27/2024	Common Stock	80,000	
	Reporting Owners												
Reporting Owner Name / Address			e / Address	Relationships									
		Director	10% Owne	r Office	r		Other						
Boulding Mark Elliott C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT SOUTH PLAINFIELD, NJ 07080						Exec	c. VP, and	CL	0				
	Signa	turos											

Signatures

/s/ Donald Mankoff Attorney-in-Fact 01/30/2014

<u>**</u>Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This option was granted on January 28, 2014, and vests over four years, with 25% of the shares underlying the option vesting on January
 (1) 1, 2015, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.